Relief Therapeutics Holding Company Description
Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally.
The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium phenylbutyrate for the treatment of urea cycle disorders; and PKU GOLIKE for the dietary management of phenylketonuria.
It also develops RLF-100, a synthetic form of vasoactive intestinal peptide for the treatment of acute respiratory distress syndrome and certain chronic lung diseases, including sarcoidosis, berylliosis, and checkpoint inhibitor-induced pneumonitis.
In addition, the company develops RLF-TD011, a hypochlorous acid solution for epidermolysis bullosa. Further, it is developing RLF-OD32, a next-generation liquid sapropterin formulation for phenylketonuria.
Relief Therapeutics Holding SA was founded in 2013 and is based in Geneva, Switzerland.
| Country | Switzerland |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
Contact Details
Address: Avenue de Secheron 15 Geneva, 1202 Switzerland | |
| Website | relieftherapeutics.com |
Stock Details
| Ticker Symbol | RLFTF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH0100191136 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jeremy Meinen CPA | Chief Financial Officer |
| Giorgio Reiner | Chief Scientific Officer |
| Paolo Galfetti | Chief Business Officer |